ADVERTISEMENTs

Shruthi Narayan promoted to President of healthcare brand, Penumbra

Narayan joined Penumbra in 2013 and has held various leadership positions since then

Shruthi Narayan / Penumbra

Penumbra, a California based healthcare device company, on Aug. 27, announced the promotion of Shruthi Narayan to President of the company.

Narayan will take office on Sept. 1, and continue to report to Adam Elsesser, who served in the role of President prior to Narayan's promotion, while continuing in his roles as Chairman of the Board and Chief Executive Officer of Penumbra.  

Narayan holds over two decades of experience in the medical device industry. She is being elevated to her new office from her previous role as President of Penumbra's interventional business, where she led the company's neuro and vascular franchises.

ALSO READ: Tripti Sinha named President and CEO of Internet2

She joined Penumbra in 2013 as a product manager and then transitioned to help build the company's peripheral vascular division. Narayan began her medical device career at Medtronic in 2006, working in engineering, regulatory affairs and then in cardiovascular sales.

"Shruthi is a dynamic, seasoned leader whose passion for innovation and proven ability to inspire global teams make her the obvious choice for this critical role," said Penumbra Chairman Elsesser.

Highlighting Narayan's defining qualities, he added, "Her vision and focus on excellence will undoubtedly help sustain Penumbra's exceptional growth and market leadership, expanding access to our life-saving technology to patients around the world."

Narayan holds a bachelor's degree in Electrical Engineering from Anna University, India and a master's degree in Biomedical Engineering from University of Southern California, with a focus on Medical Device Commercialization.

Expressing joy over her appointment, Narayan said, "Penumbra has been at the forefront of blood clot care for more than 20 years, advancing the most innovative technologies to address conditions from head-to-toe like stroke and pulmonary embolism."

She added, "I am honored to carry on and expand our legacy of innovation and look forward to continuing this paradigm shift in patient care."

Comments

Related